

May 16, 2019


Company name: Human Metabolome Technologies Inc.
 (Code number: 6090, Mothers (Tokyo Stock Exchange))

HMT obtains EU patent for Diagnostic Biomarker for Major Depressive Disorder (MDD)

Human Metabolome Technologies Inc. (HMT) President and CEO Ryuji Kanno announced today that the joint patent application for Phosphoethanolamine as a biomarker of MDD was granted in the EU. This was conducted in collaboration with Noriyuki Kawamura, Director of the Medical Corporation Association Gyo-ki kai Kawamura General Clinic (Minato-ku, Tokyo), and has officially been accepted and granted in the European market. This is in addition to the registration of the patents in Japan, USA, and China. The corresponding patent identification numbers are 5372213 in Japan), US8951739 in the USA and ZL201080046087.6 in China). The EU patent grant will not have any impact on business performance.

Name of invention: Phosphoethanolamine as a biomarker for MDD
 Patent holder: HMT and Noriyuki Kawamura
 Application no.: 10808255.3

Below is a diagram regarding patents for HMT biomarkers associated with MDD .



※About Human Metabolome Technologies Inc. (HMT)

HMT is a bioventure established in 2003 based on research results obtained by the Institute for Advanced Biosciences, Keio University in Japan. HMT provides metabolite analysis services for researchers, corporations, and public research institutions. HMT is currently working on the development of clinical testing that utilizes biomarkers capable of objectively assessing specific diseases. HMT is listed on Mothers (Tokyo Stock Exchange) in December 2013. (<http://humanmetabolome.com/>)

Public Relation Inquires
Human Metabolome Technologies Inc.
Head of IR
Kenji Sasabe
TEL 03-3551-2180 FAX 03-3551-2181
invre1@humanmetabolome.com

END